Literature DB >> 22251077

Recent advances in therapeutic cancer vaccines.

Jeffrey Schlom1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22251077      PMCID： PMC3282014          DOI： 10.1089/cbr.2012.1200

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN： 1084-9785            Impact factor:   3.099


× No keyword cloud information.
  48 in total

Review 1.  Immune resistance orchestrated by the tumor microenvironment.

Authors:  Thomas F Gajewski; Yuru Meng; Christian Blank; Ian Brown; Aalok Kacha; Justin Kline; Helena Harlin
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

Review 2.  Immune suppression in the tumor microenvironment.

Authors:  Thomas F Gajewski; Yuru Meng; Helena Harlin
Journal:  J Immunother       Date:  2006 May-Jun       Impact factor: 4.456

3.  The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses.

Authors:  Mala Chakraborty; Jeffrey Schlom; James W Hodge
Journal:  Cancer Immunol Immunother       Date:  2007-02-23       Impact factor: 6.968

Review 4.  Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.

Authors:  Thomas F Gajewski
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

5.  Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.

Authors:  Takashi Mine; Satoko Matsueda; Yufeng Li; Hiroshi Tokumitsu; Hui Gao; Cristopher Danes; Kwong-Kwok Wong; Xinhui Wang; Soldano Ferrone; Constantin G Ioannides
Journal:  Cancer Immunol Immunother       Date:  2008-12-02       Impact factor: 6.968

6.  Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.

Authors:  Jennifer S Ko; Arnold H Zea; Brian I Rini; Joanna L Ireland; Paul Elson; Peter Cohen; Ali Golshayan; Patricia A Rayman; Laura Wood; Jorge Garcia; Robert Dreicer; Ronald Bukowski; James H Finke
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

7.  Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.

Authors:  Ravi A Madan; James L Gulley; Jeffrey Schlom; Seth M Steinberg; David J Liewehr; William L Dahut; Philip M Arlen
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

Review 8.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

9.  Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

Authors:  James H Finke; Brian Rini; Joanna Ireland; Patricia Rayman; Amy Richmond; Ali Golshayan; Laura Wood; Paul Elson; Jorge Garcia; Robert Dreicer; Ronald Bukowski
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

10.  Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.

Authors:  Charlie T Garnett; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531
View more
  5 in total

Review 1.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

2.  Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment.

Authors:  Yunqing Xie; Lijie Huang; Luchuan Chen; Xiaowei Lin; Li Chen; Qiuhong Zheng
Journal:  World J Surg Oncol       Date:  2017-11-28       Impact factor: 2.754

3.  Prostate cancer vaccines: Update on clinical development.

Authors:  Sean M Geary; Aliasger K Salem
Journal:  Oncoimmunology       Date:  2013-04-29       Impact factor: 7.723

4.  Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.

Authors:  Gregory T Wurz; Audrey M Gutierrez; Brittany E Greenberg; Daniel P Vang; Stephen M Griffey; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  J Transl Med       Date:  2013-03-13       Impact factor: 5.531

5.  Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.

Authors:  Daiqing Gao; Changyou Li; Xihe Xie; Peng Zhao; Xiaofang Wei; Weihong Sun; Hsin-Chen Liu; Aris T Alexandrou; Jennifer Jones; Ronghua Zhao; Jian Jian Li
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.